title: Parathyroid hormone update.
abstract: PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to tes longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximum gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.
authors.affiliation: Division of Endocrinology, Clinical Nutrition, and Vascular Medicine, University of California Davis Medical Center, 4150 V Street, Suite G400, Sacramento, CA 95817, USA. kendal.hamann@ucdmc.ucdavis.edu
authors.forename: Kendal L
authors.initials: KL
authors.lastname: Hamann
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Lane
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000502:physiology / Q000627:therapeutic use*
chemical_list: D010281:Parathyroid Hormone